CSI Market
Sign In | Register

Autolus Therapeutics Plc (AUTL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AUTL quarterly Cash Flow →
The table below presents a historical view of Autolus Therapeutics Plc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-287.53
Depreciation & amortization8.30
Amortization of Other Assets1.52
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges2.40
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase40.25
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.01
Share-based Compensation14.44
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized2.16
Employee Benefits And Share Based Compensation Noncash14.44
Increase Decrease In Net Operating Lease Right Of Use Assets-
Increase Decreasein Accrued Liabilities Lease Liability And Other Liabilities-
Gain Loss On Incentive And Reassessment-
Gain Loss On Termination Of Lease-
Operating Lease Impairment Loss0.35
Increase Decrease In Accrued Liabilities Lease Liability And Other Liabilities1.04
Noncash Operating Lease Expense-4.30
Income taxes-0.63
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable24.16
Increase (Decrease) in Accounts Payable1.30
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.29
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities37.15
Discontinued operations0.00
Net Cash flow from Operating Activities-283.57
Investing Activities
Capital Expenditures8.09
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities428.21
Payments to Acquire Available-for-sale Securities, Debt242.62
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities158.46
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-234.31
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents228.81
Capital Expenditures Incurred But Not Yet Paid1.16
Proceeds From Issuance Of Contract With Customer Liability-
Payment Of Contract With Customer Liability Issuance Costs-
Payments For Royalties And Milestones-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4.34
Effect of exchange rate on cash flow6.28
Discontinued operations0.00
Free Cash Flow-275.48
Total Cash Flow-123.17
4 historic quarters locked

Sign in to unlock the full Autolus Therapeutics Plc cash flow history.

Sign In Create Free Account

About Autolus Therapeutics Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001730463-26-000038

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License